Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study
Table 2
Values broken down according to Helicobacter pylori infection status (univariate analysis).
Parameter
Subjects without H. pylori infection ()
Subjects with H. pylori infection ()
value
Ethnicity
0.157
Arabs ()
1,841 (83.3% of H. pylori subjects, 87.7% of Arabs)
259 (86.6% of H. pylori subjects, 12.3% of Arabs)
Jews ()
368 (16.7% of H. pylori subjects, 90.2% of Jews)
40 (13.4% of H. pylori subjects, 9.8% of Jews)
BMI
0.297
Sociodemographic status
0.256
Rural ()
1,333 (60.3% of H. pylori subjects, 87.5% of rural subjects)
191 (63.9% of H. pylori subjects, 12.5% of rural subjects)
Urban ()
876 (39.7% of H. pylori subjects, 89.0% of urban subjects)
108 (36.1% of H. pylori subjects, 11.0% of urban subjects)
Age
Gender
0.902
Males ()
1,053 (47.7% of H. pylori subjects, 88.2% of males)
141 (47.2% of H. pylori subjects, 11.8% of males)
Females ()
1,156 (52.3% of H. pylori subjects, 88.0% of females)
158 (52.8% of H. pylori subjects, 12.0% of females)
Smoking status ()
1,406 (63.6% of H. pylori subjects, 84.1% of smokers)
266 (89.0% of H. pylori subjects, 15.9% of smokers)
Alcohol consumption ()
82 (3.7% of H. pylori subjects, 85.4% of alcohol consumers)
14 (4.7% of H. pylori subjects, 14.6% of alcohol consumers)
0.421
Comorbidities ()
222 (10.0% of H. pylori subjects, 85.7% of subjects with comorbidities)
37 (12.4% of H. pylori subjects, 14.3% of subjects with comorbidities)
0.224
ASA/NSAID users ()
613 (27.8% of H. pylori subjects, 90.1% of ASA/NSAID users)
67 (22.4% of H. pylori subjects, 9.9% of ASA/NSAID users)
0.052
Statin users ()
164 (7.4% of H. pylori subjects, 86.3% of statin users)
26 (8.7% of H. pylori subjects, 13.7% of statin users)
0.416
PPI users ()
1,314 (59.5% of H. pylori subjects, 84.4% of PPI users)
242 (80.9% of H. pylori subjects, 15.6% of PPI users)
ASA: acetylsalicylic acid; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.
